Skip to content

Savara SVRA Deferred Tax Assets and Other Non-Current Assets

Deferred Tax Assets and Other Non-Current Assets at other companies

XER
Xeris Biopharma Holdings, Inc.XERS
Innoviva, Inc. logo
Innoviva, Inc.INVA
Theravance Biopharma logo
Theravance BiopharmaTBPH
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
TRV
Trevi Therapeutics, Inc.TRVI

Other financials

Income statement

See full
Revenue-
Operating income-$39.0M-37.1%
Net income-$37.3M-40.0%
EPS (diluted)-$0.15-25.0%

Balance sheet

See full
Cash & equivalents$38.8M+98.4%
Total debt$30.1M+1.8%
Total equity$176.0M+19.1%
Total assets$221.6M+17.1%

Cash flow

See full
Operating cash flow-$33.0M-21.5%
CapEx$54.0K+1,700%
Free cash flow-$33.1M-21.7%

Valuation

See full
Market cap$1.19B+134%
Enterprise value$1.19B+127%
P/S4,648.7×

Profitability

See full
Operating margin-19,183.3%
Net margin-19,305.1%
FCF margin-15,518.7%

Returns & leverage

See full
Return on equity-80%+4.7pp
Debt / equity0.2×0.0×
Current ratio13.5×-1.4×

Where this comes from

Reported directly by Savara in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.

The official record: Savara’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Savara's deferred tax assets and other non-current assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Savara's deferred tax assets and other non-current assets?
Savara (SVRA) reported deferred tax assets and other non-current assets of $886K in Q1 2026.
How has Savara's deferred tax assets and other non-current assets changed year-over-year?
Savara's deferred tax assets and other non-current assets decreased by 11.5% year-over-year, from $1M to $886K.
What is the long-term trend for Savara's deferred tax assets and other non-current assets?
Over 5 years (2020 to 2025), Savara's deferred tax assets and other non-current assets has grown at a -19.6% compound annual growth rate (CAGR), from $250K to $84K.